Published in Antimicrob Agents Chemother on November 01, 2002
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother (2009) 2.41
Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol (2006) 2.15
One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol (2007) 1.87
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol (2010) 1.68
Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol (2007) 1.58
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol (2005) 1.55
Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol (2007) 1.55
Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother (2007) 1.48
Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol (2005) 1.12
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother (2008) 1.11
Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. J Clin Microbiol (2008) 1.05
Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis (2004) 1.02
Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods. J Clin Microbiol (2012) 0.98
Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates. J Clin Microbiol (2011) 0.97
Synthesis and Antimycobacterial Activity of Symmetric Thiocarbohydrazone Derivatives against Mycobacterium bovis BCG. Iran J Pharm Res (2013) 0.94
Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res (2011) 0.92
In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob Agents Chemother (2004) 0.90
Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression. Antimicrob Agents Chemother (2005) 0.85
Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob Agents Chemother (2010) 0.81
Comparison of caspofungin MICs by means of EUCAST method EDef 7.1 using two different concentrations of glucose. Antimicrob Agents Chemother (2010) 0.80
Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. Antimicrob Agents Chemother (2007) 0.80
Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts. Antimicrob Agents Chemother (2008) 0.78
Clotrimazole Drug Resistance in Candida glabrata Clinical Isolates Correlates with Increased Expression of the Drug:H(+) Antiporters CgAqr1, CgTpo1_1, CgTpo3, and CgQdr2. Front Microbiol (2016) 0.78
Macelignan inhibits bee pathogenic fungi Ascophaera apis growth through HOG1 pathway. Braz J Med Biol Res (2016) 0.75
Multicenter comparison of the ISO standard 20776-1 and the serial 2-fold dilution procedures to dilute hydrophilic and hydrophobic antifungal agents for susceptibility testing. J Clin Microbiol (2010) 0.75
Antifungal indole and pyrrolidine-2,4-Dione derivative peptidomimetic lead design based on in silico study of bioactive Peptide families. Avicenna J Med Biotechnol (2013) 0.75
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother (1998) 4.95
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol (1998) 2.65
Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol (2001) 2.23
Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother (2000) 2.22
Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother (2002) 2.20
Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother (1995) 2.07
Standardization of antifungal susceptibility variables for a semiautomated methodology. J Clin Microbiol (2001) 1.31
In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother (2000) 1.21
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med (2008) 4.68
Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol (2004) 4.51
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2005) 3.41
Multiple-triazole-resistant aspergillosis. N Engl J Med (2007) 3.33
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis (2009) 3.03
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother (2006) 2.76
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 2.41
Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother (2002) 2.20
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother (2008) 2.17
Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother (2005) 1.92
In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother (2004) 1.88
Assessment of ribosomal large-subunit D1-D2, internal transcribed spacer 1, and internal transcribed spacer 2 regions as targets for molecular identification of medically important Aspergillus species. J Clin Microbiol (2005) 1.86
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother (2010) 1.82
Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2006) 1.81
Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol (2004) 1.66
In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother (2004) 1.62
An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001. J Infect Dis (2005) 1.60
Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother (2005) 1.52
Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis (2004) 1.51
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin Microbiol (2012) 1.49
Histoplasmosis associated with exploring a bat-inhabited cave in Costa Rica, 1998-1999. Am J Trop Med Hyg (2004) 1.47
In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2003) 1.40
Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother (2008) 1.37
Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother (2006) 1.37
Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol (2011) 1.35
Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother (2007) 1.33
G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother (2003) 1.28
Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother (2005) 1.25
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother (2009) 1.23
Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids (2007) 1.22
Resolution of discrepant results for Candida species identification by using DNA probes. J Clin Microbiol (2004) 1.21
Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother (2008) 1.17
Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med (2004) 1.15
Evidence for aneuploidy and recombination in the human commensal yeast Candida parapsilosis. Infect Genet Evol (2004) 1.13
Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother (2003) 1.10
Members of protein O-mannosyltransferase family in Aspergillus fumigatus differentially affect growth, morphogenesis and viability. Mol Microbiol (2010) 1.09
Stability of allelic frequencies and distributions of Candida albicans microsatellite loci from U.S. population-based surveillance isolates. J Clin Microbiol (2003) 1.09
In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother (2004) 1.08
Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents. Antimicrob Agents Chemother (2003) 1.08
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother (2009) 1.07
Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med Mycol (2010) 1.06
Prevalence and susceptibility testing of new species of pseudallescheria and scedosporium in a collection of clinical mold isolates. Antimicrob Agents Chemother (2006) 1.06
Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother (2005) 1.06
Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother (2002) 1.05
Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility. Antimicrob Agents Chemother (2006) 1.05
Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol (2008) 1.03
Fungal infections among returning travelers. Clin Infect Dis (2002) 1.03
Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus. Antimicrob Agents Chemother (2005) 1.02
Analysis of the influence of Tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp. J Clin Microbiol (2005) 1.02
Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropenia. J Clin Microbiol (2008) 1.02
In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother (2008) 1.01
Environmental influences on the phenology and abundance of flowering by Androsace septentrionalis (Primulaceae). Am J Bot (2003) 1.00
Role of Aspergillus lentulus 14-α sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrob Agents Chemother (2011) 1.00
In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother (2002) 0.99
Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J (2006) 0.99
Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Med Mycol (2008) 0.98
A new approach to drug discovery: high-throughput screening of microbial natural extracts against Aspergillus fumigatus using resazurin. J Biomol Screen (2012) 0.98
Current status of antifungal resistance and its impact on clinical practice. Br J Haematol (2014) 0.97
Genotyping and antifungal susceptibility profile of Dipodascus capitatus isolates causing disseminated infection in seven hematological patients of a tertiary hospital. J Clin Microbiol (2004) 0.97
Ergosterol biosynthesis in Aspergillus fumigatus: its relevance as an antifungal target and role in antifungal drug resistance. Front Microbiol (2013) 0.97
Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J Clin Microbiol (2008) 0.96
Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia. Rev Iberoam Micol (2012) 0.96
In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus. Med Mycol (2010) 0.95
Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother (2005) 0.94
Identification of pathogenic rare yeast species in clinical samples: comparison between phenotypical and molecular methods. J Clin Microbiol (2010) 0.94
In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother (2005) 0.94